Skip to main content

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

Active, not recruiting · Phase 2 · NCT06914908

Conditions: Chronic Rhinosinusitis With Nasal Polyps

At a glance

Research payments reported, 2025
$143,124
U.S. investigators named
5
Sites paid
5
Planned or actual enrollment
71

About the trial

Sponsor
Sanofi
Tested
Lunsekimig (drug), Mometasone furoate nasal spray (MFNS) (drug)
Dates
Started 2025-05-12; completion 2029-02-22
Results posted
Not yet

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 148 weeks per participant, including 144 weeks of treatment period and 4 weeks of follow-up.

From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $143,124 in research payments for this study in 2025 (24 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Treasure Valley Medical Research Neetu Talreja $49,090
  • Brian D Modena Orso Health Inc $40,632
  • Alamo Ent Associates $23,202
  • Berkson Medical Llc $17,600
  • Essential Medical Research LLC $12,600

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.